Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Tempest Therapeutics ( (TPST) ) is now available.
On May 22, 2026, Tempest Therapeutics, Inc. announced that directors Stephen Brady, Michael Raab and Christine Pellizzari resigned from its board of directors, with the company stating it had not been informed of any disagreements related to operations, policies or practices. In connection with the transition, each departing director entered into a separation agreement waiving accrued and unpaid retainer fees while retaining rights to existing stock option awards, share ownership and indemnification protections, which will remain in effect for six years following separation, signaling an orderly governance change for stakeholders.
The company indicated that these arrangements are consistent with its non-employee director compensation framework, as previously disclosed in regulatory filings, and that the resignations and related terms do not alter the underlying rights embedded in its certificate of incorporation and bylaws. The treatment of equity awards and continued indemnification should help provide continuity and reduce potential legal or financial uncertainty as Tempest Therapeutics adjusts its board composition and oversight structure.
The most recent analyst rating on (TPST) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.
Spark’s Take on TPST Stock
According to Spark, TipRanks’ AI Analyst, TPST is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses/cash burn, and a sharply weakened balance sheet with high leverage). Technicals are only neutral with modest short-term improvement but a still weak longer-term trend. Positive clinical-data headlines help the outlook, but near-term funding/dilution risk remains a major constraint.
To see Spark’s full report on TPST stock, click here.
More about Tempest Therapeutics
Tempest Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics, operating within the biopharmaceutical industry. The company’s activities center on advancing its drug candidates and managing its corporate governance structure as it navigates the competitive biotech and capital markets environment.
Average Trading Volume: 197,990
Technical Sentiment Signal: Sell
Current Market Cap: $27.54M
See more data about TPST stock on TipRanks’ Stock Analysis page.